Table 1.
Characteristics of STI testing services within PrEP programmes (N = 91)
| Programme indicators | n (%) |
|---|---|
| Country income level | |
| High‐income | 63 (69%) |
| Low‐ or middle‐income | 28 (31%) |
| First year of data | |
| Before 2013 | 13 (14%) |
| 2013 to 2015 | 31 (34%) |
| After 2016 | 47 (52%) |
| PrEP users population | |
| MSM/TGW | 58 (64%) |
| Mixed population a | 33 (36%) |
| Programme services site | |
| Hospital and sexual health clinic | 50 (55 %) |
| A mix of hospital and community clinic | 20 (22%) |
| Community‐based organizations/settings | 18 (20%) |
| General practice | 3 (3%) |
| Type of study | |
| Routine implementation | 28 (31%) |
| Open‐label cohort study | 39 (43%) |
| Demonstration project | 17 (19%) |
| Randomized controlled trial | 7 (8%) |
| Provided STI testing before PrEP initiation | |
| Yes | 64 (70%) |
| Not stated | 27 (30%) |
| Provided gonorrhoea testing | |
| Yes | 78 (86%) |
| Not stated | 13 (14%) |
| Gonorrhoea testing frequency (N = 78) | |
| Every three months or shorter interval | 53 (68%) |
| Every six months | 17 (22%) |
| Every twelve months or longer | 4 (5%) |
| Not stated | 4 (5%) |
| Gonorrhoea testing methods (N = 78) | |
| Molecular testing | 56 (72%) |
| Not stated | 22 (28%) |
| Provided chlamydia testing | |
| Yes | 76 (84%) |
| Not stated | 15 (16%) |
| Chlamydia testing frequency (N = 76) | |
| Every three months or shorte | 53 (70%) |
| Every six months | 17 (22%) |
| Every twelve months or longer | 4 (5%) |
| Not stated | 2 (3%) |
| Provided syphilis testing | |
| Yes | 76 (84%) |
| Not stated | 15 (16 %) |
| Syphilis testing frequency (N = 76) | |
| Every three months or shorter | 53 (70%) |
| Every six months | 15 (20%) |
| Every twelve months or longer | 5 (6%) |
| Not stated | 3 (4%) |
| Syphilis testing method (N = 76) | |
| Serology | 41 (54%) |
| Rapid diagnostic test | 11 (14%) |
| PCR | 2 (3%) |
| Not stated | 22 (29%) |
| Provided Hepatitis A testing | |
| Yes | 12 (13%) |
| Not stated | 79 (87%) |
| Hepatitis A testing frequency (N = 12) | |
| At baseline only | 6 (50%) |
| Every three months | 5 (42%) |
| Every twelve months | 1 (8%) |
| Provided Hepatitis A vaccination | |
| Yes | 8 (9%) |
| Not stated | 83 (91%) |
| Provided Hepatitis B testing | |
| Yes | 48 (53%) |
| Not stated | 43 (47%) |
| Hepatitis B testing frequency (N = 48) | |
| Every three months | 14 (29%) |
| Every six months | 2 (4%) |
| Every twelve months | 5 (10%) |
| At baseline only | 18 (38%) |
| Not stated | 9 (19%) |
| Provided Hepatitis B vaccination | |
| Yes | 17 (19%) |
| Not stated | 74 (81%) |
| Provided Hepatitis C testing | |
| Yes | 33 (36%) |
| Not stated | 58 (64%) |
| Hepatitis C testing frequency (N = 33) | |
| Every three months | 10 (30%) |
| Every six months | 5 (15 %) |
| Every twelve months | 6 (18%) |
| At baseline only | 5 (15%) |
| Not stated | 7 (22%) |
| Provided human papillomavirus vaccination | |
| Yes | 5 (6%) |
| Not stated | 86 (94 %) |
| Number of STIs tested b (Range: 0 to 6) | |
| Mean (SD) | 3.53 (1.59) |
| Median (interquartile range) | 3 (3 to 5) |
| Provided additional sexual health services c | |
| Yes | 48 (53%) |
| Not stated | 43 (47%) |
| Triple anatomical site screening available d | |
| Yes | 39 (43%) |
| Not stated | 52 (57%) |
| Provided antimicrobial resistance testing | |
| Yes | 7 (8%) |
| Not stated | 84 (92%) |
MSM, men who have sex with men; SD, standard deviation; STI, sexually transmitted infection; TGW, transgender women.
a
Mixed population included sero‐discordant couples, female sex workers, cis‐gender females, transgender men, people who use drugs and heterosexuals
b
types of STIs tested included gonorrhoea, chlamydia, syphilis, Hepatitis A, Hepatitis B, Hepatitis C
c
additional sexual health services include vaccination, free condoms, counselling, partner notification services, etc.
d
triple site screening availability is defined as whether the use of throat, urethra/urine and anorectal samples were available at the clinic.